TP53 and Therapy-related Myeloid Neoplasms

Publication date: Available online 19 February 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Jae Chung, David A. Sallman, Eric PadronAbstractTherapy-related myeloid neoplasms (t-MNs) are the most serious late complications in patients treated with traditional cytotoxic chemotherapy and/or radiation. T-MNs are aggressive and chemorefractory hematologic malignancies, with a median survival of less than 6 months. TP53 mutations are highly enriched in t-MN patients, though the mechanism for this selective enrichment has only come to light over the past several years. In this review, we discuss the history and function of p53, and the role of TP53 mutations in the origin and progression of t-MNs. Emerging data has begun to elucidate who may be at highest risk of developing t-MNs, which ideally will enable us to develop preventative strategies for this devastating disease. As t-MNs may not be avoidable, novel therapies are urgently needed for this patient group and are underway as exemplified by recent investigation in restoring wild-type p53 function as well as directly targeting TP53 mutant variants. With better prevention and treatment, outcomes will hopefully begin to improve in the near future.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research

Related Links:

Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractPurposeTo report outcomes of salvage re-irradiation (re-RT) in recurrent/progressive medulloblastoma (MB).MethodsMedical records of patients treated with curative-intent re-RT as multi-modality management for recurrent/progressive MB between 2008 and 2018 were analyzed retrospectively.ResultsA total of 28 patients (median age 18  years at index diagnosis) were included. Molecular subgrouping was done using real-time reverse transcriptase polymerase chain reaction (RT-PCR) based on the differential expression of select set of 12 protein coding genes and 9 microRNAs. Fifteen of 17 (88%) patients with sonic hedge...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsOur results suggest a role of decreased MPC1 copy number segments in reducing overall survival in glioblastoma. MPC1 deletion is associated with poor response to TMZ chemotherapy in GBM.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 August 2019Source: Molecular Genetics and MetabolismAuthor(s): Peter K. RoganAbstractPharmacogenomic responses to chemotherapy drugs can be modeled by supervised machine learning of expression and copy number of relevant gene combinations. Such biochemical evidence can form the basis of derive gene signatures using cell line data, which can subsequently be examined in patients that have been treated with the same drugs. These gene signatures typically contain elements of multiple biochemical pathways which together comprise multiple origins of drug resistance or sensitivity. The signat...
Source: Molecular Genetics and Metabolism - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 17 August 2019Source: Life SciencesAuthor(s): Masoud Najafi, Keywan Mortezaee, Jamal MajidpoorAbstractCancer stem cells (CSCs) are a population of self-renewal cells with high tumorigenic potency. CSCs can adopt easily with changes in the nearby milieu, and are more resistant to conventional therapies than other cells within a tumor. CSC resistance can be induced secondary to radio- and chemotherapy, or even after chemotherapy secession. A combination of both intrinsic and extrinsic factors is contributed to CSC-mediated therapy resistance. CSCs represent protective autophagy and efficien...
Source: Life Sciences - Category: Biology Source Type: research
ConclusionOur data demonstrate that AURKA inhibition induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma. The combination of MLN8237 and conventional chemotherapy showed promising safety and anti-tumor activities in preclinical models of Myc-positive NHL.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
SummaryPurpose Anorexia induced by cytotoxic chemotherapy on delayed phase is a highly frequent adverse event. We aimed to determine the effects of rikkunshito (RKT) on chemotherapy-induced anorexia (CIA) in patients with lung cancer.Methods This prospective, randomized, cross-over pilot trial included 40 lung cancer patients scheduled to undergo cisplatin-based chemotherapy and randomized to either a group given RKT 7.5  g/day for 14 days (Group A,N = 20) or not (Group B,N = 20), then the treatments were switched. All patients received dexamethasone, palonosetron hydrochloride and apr...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
ConclusionPatients with localized extraskeletal ES have comparable OS outcomes to patients with skeletal ES utilizing the standard VDC-IE chemotherapy. However, extraskeletal patients are at significantly higher risk for local recurrence.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: We demonstrated for the first time the prognostic significance of adnexal CRS confirming also the prognostic role of omental CRS.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPhysicians should be aware of the possibility of the emergence of primary malignancies in patients with a history of papillary thyroid carcinoma, especially lung cancer as it is a common site of papillary thyroid carcinoma metastases. Using appropriate diagnostic evaluations in order to choose the best therapeutic option is of utmost importance.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
More News: Cancer & Oncology | Chemotherapy | Hematology